Congress Materials
As part of our commitment to addressing unmet medical needs, Corcept investigates approved products and pipeline compounds and indications. Corcept presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. The safety and efficacy of investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities.
Access Corcept congress presentations below.
Filter by:
Society of Gynecologic Oncology (SGO) Annual Meeting
2023
ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer
Olawaiye AB, Van Gorp T, Monk BJ, et al.
American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
2023
Phase 1 Efficacy and Pharmacodynamic Results of Exicorilant + Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Morris MJ, Linch M, Crabb SJ, et al.
Annual Meeting of The Endocrine Society
2022
Impact of mifepristone on liver function and liver steatosis in patients with Cushing syndrome
East HE, Moraitis AG, Belanoff J
Annual Meeting of The Endocrine Society
2022
Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with Cushing syndrome
Moraitis AG, Custodio JM, Tudor CT
European Congress of Endocrinology
2022
Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with Cushing syndrome
Moraitis AG, Custodio JM, Tudor CT
American Association of Clinical Endocrinology
2022
Mifepristone use in hypercortisolism from an unknown source: a case study
Brown DR, Ray R
International Gynecologic Cancer Society (IGCS) Annual Global Meeting
2022
Phase 2 Results of Relacorilant + Nab-Paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer with and Without Prior Bevacizumab
Colombo N, Van Gorp T, Matulonis UA, et al.
European Society for Medical Oncology (ESMO) Congress
2022
Glucocorticoid Receptor Expression and Activity in a Phase 2 Ovarian Cancer Trial of the Glucocorticoid Receptor Modulator Relacorilant in Combination with Nab-Paclitaxel
Lorusso D, Greenstein AE, Wadekar S, et al.
European Society for Medical Oncology (ESMO) Congress
2022
Phase 1 Results of Exicorilant + Enzalutamide in Patients with Castration-Resistant Prostate Cancer
Linch M, Liu G, Crabb SJ, et al.
European Society for Medical Oncology (ESMO) Congress
2022
Relacorilant + Nab-paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer: Phase 2 Subgroup Analysis Mirroring the Patient Population of an Upcoming Phase 3 Study
Colombo N, Van Gorp T, Matulonis UA, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2022
Overall survival data from a 3-arm randomized phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer
Colombo N, Van Gorp T, Matulonis UA, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2022
A study of relacorilant in combination with nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma (mPDAC)
Borazanci EH, Bahary N, Chung V, et al.
Annual Meeting of The Endocrine Society
2021
Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production
Habra MA, Hammer GD, Kebebew E, Worden FP, Raj N, Hallanger-Johnson JE, Grauer A, Moriatis A
American Association of Clinical Endocrinology
2021
Prevalence of Hypercortisolism in Patients With Adrenal Adenoma(s) and Type 2 Diabetes Mellitus: Findings From an Electronic Medical Records (EMR) Search
Sachmechi I, Salam S, Umair M, Tarnowski KW
American Association of Clinical Endocrinology
2021
Use of Mifepristone in a Hypercortisolemic Patient With End-Stage Renal Disease on Hemodialysis
Coo AW, Ray R
European Society for Medical Oncology (ESMO) Congress
2021
Relacorilant, A Selective Glucocorticoid Receptor Modulator, In Combination With Nab-Paclitaxel Improves Progression-Free Survival In Patients With Recurrent Platinum-Resistant Ovarian Cancer: A 3-Arm, Randomized, Open-Label, Phase 2 Study
Lorusso D, Colombo N, Nguyen D, et al.
Annual Meeting of The Endocrine Society
2020
GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia
Auchus, RJ, Grauer A, Moriatis AG
European Congress of Endocrinology
2020
A Double-Blind, Randomized, Placebo-Controlled Phase 3 Study to Assess the Efficacy and Safety of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Patients With Hypercortisolism Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia
Chiodini Grauer A, Moriatis AG, Terzolo M
European Congress of Endocrinology
2020
Excess Glucocorticoid Activity May Suppress Tumor Immune Activity in Adrenocortical Carcinoma
Greenstein AE, Habra MA, Mura M, Biernat P, Piatek MJ, Grauer A, Shepherd SP
American Association for Cancer Research (AACR) Annual Meeting
2020
Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid
Greenstein AE, Habra MA, Mura M, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2020
Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol
Greenstein AE, Munster PN, Sachdev JC, et al.
Annual Meeting of The Endocrine Society
2019
A Randomized-Withdrawal, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Selective Glucocorticoid Receptor Antagonist, Relacorilant, in Patients With Cushing Syndrome (GRACE Study)
Auchus RJ, Findling JW, Moriatis AG
Annual Meeting of The Endocrine Society
2019
Sustained Clinical Improvement After Discontinuation of Mifepristone: Unexpected Remission of Hypercortisolism
Anderson R, Pesa N, Kassar A
Annual Meeting of The Endocrine Society
2019
Anticipating Hypokalemia in Patients With ACTH-Dependent Cushing Syndrome Treated With Mifepristone: Utilization of Cortisol and ACTH Levels to Identify At-Risk Patients
Moraitis AG, Nguyen
Annual Meeting of The Endocrine Society
2019
Tumor Shrinkage With Preoperative Relacorilant Therapy in Two Patients With Cushing Disease due to Pituitary Macroadenomas
Terzolo M, Iacuaniello D, Pia A, Adriano P, Moriatis A, Pivonello R
American Association of Clinical Endocrinology
2019
Improvement in Muscle Strength and Psychiatric Symptoms in a Patient With Persistent Cushing Disease Treated With Mifepristone
Yacoub T, Palaniswamy K
American Association of Clinical Endocrinology
2019
Clinical Consequences of an Untreated Cortisol-Producing Adrenal Adenoma: A 10-Year History
Jerkins TW, Jerkins RK, Ray R
American Association of Clinical Endocrinology
2019
Prevalence of Hypercortisolism in Patients With Type 2 Diabetes Mellitus With Incidentally Found Adrenal Adenomas: An Interim Analysis
Sachmechi I, Alkomos MF, Zarghamravanbaksh P, Mahendhar R, Palaniswamy K
American Association of Clinical Endocrinology
2019
Mifepristone Provides Beneficial Clinical Improvement in Two Cushing Disease Cases in a Community Endocrinology Practice
Iweha C, Chavez D
American Association of Clinical Endocrinology
2019
Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator, Relacorilant (up to 400 mg/day), in Patients With Endogenous Hypercortisolism: Results From an Open-Label Phase 2 Study
Pivonello R, Kargi A, Ellison N, Moriatis A, Terzolo M
American Society of Clinical Oncology (ASCO) Annual Meeting
2019
Relacorilant With Nab-paclitaxel: Safety and Activity in Patients With Pancreatic Ductal Adenocarcinoma and Ovarian Cancer
Munster PN, Sachdev JC, Fleming GF, et al.
Annual Meeting of The Endocrine Society
2018
Mifepristone therapy prior to pituitary surgery in Cushing disease prevented need for long-term glucocorticoid replacement
Sack PA Smith JJ
Annual Meeting of The Endocrine Society
2018
A curious case of biochemical and clinical remission after treatment with mifepristone, a glucocorticoid receptor antagonist
Cohan P, Kelly DF, Lim PJ
Annual Meeting of The Endocrine Society
2018
Administration of localized progestin before mifepristone treatment may prevent endometrial thickening and breakthrough bleeding
O’Dea JP, Lin PJ
Annual Meeting of The Endocrine Society
2018
Combining amiloride and spironolactone to manage hypokalemia and edema in patients with Cushing syndrome being treated with mifepristone
Cheng J, Bunta RL, Haider A
Annual Meeting of The Endocrine Society
2018
FKBP5 gene expression biomarker in ACTH-dependent Cushing syndrome patients pre- and postsurgery
Bancos I, Hatipoglu BA, Ji Yuen KC, Moriatis A
American Association of Clinical Endocrinology
2018
Phenotypic and metabolic improvements in a patient with equivocal findings of hypercortisolism treated with mifepristone: photographic and radiographic evidence
Thomas MJ, Smith JJ
American Association of Clinical Endocrinology
2018
Marked improvement in metabolic parameters in a patient with ACTH-independent hypercortisolism while on mifepristone
Ray R, Bunta R, Dauphin P
American Association of Clinical Endocrinology
2018
Mifepristone decreased the use of concentrated u500 insulin in patients with endogenous hypercortisolism who have type 2 diabetes mellitus
Mathews JW, Smith JJ
American Association of Clinical Endocrinology
2018
Open-label phase 2 study to assess safety and efficacy of relacorilant (cort125134), a selective cortisol modulator, in the treatment of endogenous hypercortisolism
Moraitis AG, Agrawal N, Bancos I, Celo FS, Gordon MB, Kargi AY, Lerman S, Mariash CN, Silverstein JM, Weirman ME
American Association of Clinical Endocrinology
2017
Mifepristone reduced u500 insulin usage in a patient with Cushing disease and normalized concomitant fatty liver disease and retinopathy
Bourne KA, Smith JJ
American Association of Clinical Endocrinology
2017
Screening of diabetic patients using u500 insulin uncovers a high percentage of undiagnosed hypercortisolism consistent with Cushing syndrome
Mathews JW, Smith JJ
American Association of Clinical Endocrinology
2017
Improving glycemic control with mifepristone in Cushing syndrome patients may lead to significant weight-loss
Ioachimescu AG, Ownby JG, Greyshock NG, Jones TC, Wand GS, Smith JJ
American Association of Clinical Endocrinology
2017
Mifepristone therapy significantly improved insulin resistance, glycemic control, and weight loss in a patient with Cushing disease previously treated with pasireotide
Ownby JG, Smith JJ
American Association of Clinical Endocrinology
2017
Medical management of mild hypercortisolism and primary aldosteronism in a patient with ACTH-independent macronodular hyperplasia presenting with resistant hypertension
Galati SJ, Lamerson M
American Association of Clinical Endocrinology
2017
Successful medical management with mifepristone in a patient with occult ectopic Cushing syndrome
Farghani S, Lamerson M
Annual Meeting of The Endocrine Society
2017
Mifepristone Treatment Effectively Improved Clinical Symptoms of Severe Hypercortisolism in a Patient With Primary Macronodular Adrenal Hyperplasia (PMAH) Allowing Surgical Treatment and Subsequent Conception
Mercado JU, Moloney K, Lim PJ, Yuen KCJ
Annual Meeting of The Endocrine Society
2017
A Case for Avoiding Unwarranted Surgery: A Patient with Primary Macronodular Adrenal Hyperplasia (PMAH) Initially Presenting as a Unilateral Adrenal Incidentaloma
Cohan P, Lim PJ, Peters AL
American Association of Clinical Endocrinology
2016
Immediate and sustained improvements in a cushing’s syndrome patient with primary macronodular adrenal hyperplasia treated with mifepristone
East, HE, Nquyen D
American Association of Clinical Endocrinology
2016
Prevention of secondary adrenal insufficiency with presurgical use of mifepristone in patients with autonomous cortisol-secreting adenomas
Parker JC, Smith JJ
Annual Meeting of The Endocrine Society
2016
Short-Term Mifepristone Treatment Improved Preoperative Clinical Status in a High-Risk Patient With Unexpected Normalization of Liver Enzymes
Andzel G, Thi Lam HN, Lim PJ
Annual Meeting of The Endocrine Society
2016
Cushing’s Syndrome Misdiagnosed as Bipolar Depression
Christofides EA, Pesa N, Nguyen D
Annual Meeting of The Endocrine Society
2016
Persistent Acromegaly Controlled on Pegvisomant with Co-Existing Non-ACTH Dependent Cushing’s Syndrome (CS) Due to Bilateral Adrenal Adenomas with Dramatic Clinical Response to Mifepristone
Gordon MB, Spiller KL, Bunta R, Gorden MS
Annual Meeting of The Endocrine Society
2016
No Incidence of Adrenal Insufficiency (AI) in Normo-cortisolemic Patients Treated With Mifepristone (MIFE): An Analysis of 5 Placebo-Controlled Clinical Trials
Cram D, Moraitis A, Nguyen D
Annual Meeting of The Endocrine Society
2015
Pre-surgical Use of Mifepristone for Ectopic Cushing’s in a High-Risk Bilateral Adrenalectomy Candidate
Madu IJ, Nguyen
Annual Meeting of The Endocrine Society
2015
Mifepristone for the Successful Treatment of Cushing’s Syndrome After Multiple Failed Interventions
Ijaz MT, Pesa N, Nguyen D
Annual Meeting of The Endocrine Society
2015
Marked Improvement in Liver Enzymes During Medical Therapy With Mifepristone for Cushing’s Syndrome
Ragucci E, Lamerson M
Annual Meeting of The Endocrine Society
2015
Treatment of Ectopic Cushing’s Syndrome With Mifepristone While Pending Tumor Localization
Rahnema MF, Chavez D, Nguyen D
American Association of Clinical Endocrinology
2015
Mifepristone Re-established Glycemic Control in a Cushing’s Syndrome Patient That Relapsed After a 21-Month Interruption
Frieze TW, Smith JJ
American Association of Clinical Endocrinology
2015
Resistant Metabolic Abnormalities Prompting Cushing’s Syndrome Work-up and Treatment With Mifepristone
Beatty DC, Bunta R, Nguyen D
American Association of Clinical Endocrinology
2015
Improved Response to Octreotide LAR for Ectopic Cushing’s Syndrome During Mifepristone Therapy: a Case Study
Moraitis A, Auchus RJ
American Association of Clinical Endocrinology
2015
Use of Mifepristone in an Ectopic Cushing’s Syndrome Patient Pending Tumor Localization
Ansari A, Lim P, Nguyen D
Annual Meeting of The Endocrine Society
2013
Quality of Life Changes in Participants of the SEISMIC Extension Trial in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Adelman DT, Howell SM, Via PS
Annual Meeting of The Endocrine Society
2013
Using Mifepristone to Differentiate Cushing's Disease From Cushing's Syndrome
Ehrenkranz JRL, Gross C, Belanoff JK
Ehrenkranz JRL, Gross C, Belanoff JK
Annual Meeting of The Endocrine Society
2013
Endometrial Effects of Long-Term Mifepristone Treatment of Cushing's Syndrome: Results From the SEISMIC Studies
Carroll T, Ioffe O, Spitz IM, Gross C, Cram D, Hamrahian A
San Antonio Breast Cancer Symposium (SABCS)
2013
A randomized phase I trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel, Abraxane®) with or without mifepristone for advanced breast cancer
Nanda R, Chennamaneni P, Gibson J, et al.
Auchus RJ, McPhaul MJ, Findling JW, Gross C
Katznelson L, Loriaux DL, Feldman D, et al